Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

✍ Scribed by Felipe García; Juan Carlos López Bernaldo de Quirós; Carmen E. Gómez; Beatriz Perdiguero; Jose L. Nájera; Victoria Jiménez; Juan García-Arriaza; Alberto C. Guardo; Iñaki Pérez; Vicens Díaz-Brito; Matilde Sánchez Conde; Nuria González; Amparo Alvarez; José Alcamí; José Luis Jiménez; Judit Pich; Joan Albert Arnaiz; María J. Maleno; Agathe León; María Angeles Muñoz-Fernández; Peter Liljeström; Jonathan Weber; Giuseppe Pantaleo; José M. Gatell; Montserrat Plana; Mariano Esteban

• Book ID: 116964247
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 533 KB
• Volume: 29
• Category: Article
• ISSN: 0264-410X
• DOI: 10.1016/j.vaccine.2011.08.098